contactenos@vnovamed.com.co

Myosop®

REGISTRO SANITARIO INVIMA: SD2022-0004665

OBSERVACIONES:
ESTE PRODUCTO, ES UN SUPLEMENTO DIETARIO, NO ES UN MEDICAMENTO Y NO SUPLE UNA ALIMENTACIÓN EQUILIBRADA.

INDICACIONES:
SUPLEMENTO DIETARIO

PRINCIPIO ACTIVO:
MIOINOSITOL, ÁCIDO FÓLICO, VITAMINA D, YODO, ZINC

PRESENTACIÓN:
CAJA CONTENIENDO 30 SOBRES EN LAMINADO (POLIESTER ALUMINIO/POLIETILENO), CADA SOBRE POR 4 GRAMOS DE POLVO

REFERENCIA IMÁGENES: 

Kirsty A. Walters, Polycystic ovary syndrome: Is it androgen or estrogen receptor?, Current Opinion in Endocrine and Metabolic Research, Volume 12, 2020, Pages 1-7, ISSN 2451-9650, https://doi.org/10.1016/j.coemr.2020.01.003. (https://www.sciencedirect.com/science/article/pii/S245196502030003X)

BIBLIOGRAFÍA:

  1. Genazzani AD. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online. 2016 Dec;33(6):770-780. doi: 10.1016/j.rbmo.2016.08.024. Epub 2016 Sep 16. PMID: 27717596.
  2. DiNicolantonio JJ, H O’Keefe JMyo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetesOpen Heart 2022;9:e001989. doi: 10.1136/openhrt-2022-001989
  3. Barriga, P. et al. (2020) ‘Role of myo-inositol in polycystic ovary syndrome’, Gynecological and Reproductive Endocrinology and Metabolism , 1(4), pp. 204–207.
  4. Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29:375-9.
  5. Merviel, P., James, P., Bouée, S. et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health 18, 13 (2021). https://doi.org/10.1186/s12978-021-01073-3
  6. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009;147:120-3.
  7. Gupta D, Khan S, Islam M, Malik BH, Rutkofsky IH. Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome. Cureus. 2020 May 12;12(5):e8079. doi: 10.7759/cureus.8079. PMID: 32542134; PMCID: PMC7292722.
  8. Bizzarri M, Monti N, Piombarolo A, Angeloni A, Verna R. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Nutrients. 2023; 15(8):1875. https://doi.org/10.3390/nu15081875
  9. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes : results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288:1405–11.
  10. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol Endocrinol. 2007;23:700–3